BackgroundThep63protein,ahomologueofthetumour-suppressorp53,ishighlyexpressedinthenucleiofbasalorProgenitorlayerofmanyepithelialtissues.p63isdetectedinprostatebasalcellsinnormalprostateglandsandPIN.Othermarkersforbasalcellsarehighmolecularcytokeratins(CK1,5,10and14),whichcanbelabelledwithHMWCKclone34ßE12.Inprostateadenocarcinomabasalcellsdisappearandstainingwithbothp63andHMWCKfails.Thusthecombinationofp63andHMWCKisausefultoolasdifferentialmarkersforbenignprostateglandsandadenocarcinoma(negativemarker).nuclearp63andcytoplasmichighmolecularweightcytokeratins.

Source

Immunogen:Recombinanthumanp63protein(aa1-205)andcytokeratinextractofhumanstratumcorneum

ProductAntibodysolutioninstABIlizingphosphatebufferpH7.3.Contains0.09%sodiumazide**.Thevolumeissufficientfor250-500immunohistochemicaltests(100µlworkingsolution/test).Useappropriateantibodydiluente.g.BIOLOGOArt.No.PU002,ifdesired.

PurificationMethod:AntibodysolutioninstabilizingphosphatebufferpH7.3.Contains0.09%sodiumazide**.Thevolumeissufficientfor250-500immunohistochemicaltests(100µlworkingsolution/test).Useappropriateantibodydiluente.g.BIOLOGOArt.No.PU002,ifdesired.

SecondaryReagents:WerecommendtheuseofBIOLOGO"sUniversalStainingSystemDAB(Art.No.DA005)orAEC(Art.No.AE005),butalsootherstainingsystemsincludinganti-mouseIgGwillbesuitable

Specificity

SpeciesReactivity:Human

ApplicationsIHC(P)

IncubationTime:30-60min

WorkingConcentration:(RTU)neat

Pre-Treatment:Useformalin-fixedandparaffin-embeddedsections;Retrievalconditions:UnmaskingfluidT,TECbuffer(Tris/EDTA/Citrate)pH8(Art.No.DE005)inapressurecookerat100°C20-40minutes

PositiveControl:Normalprostatetissueorskin

Storage2-8°C

CautionThisproductisintendedFORRESEARCHUSEONLY,andFORTESTSINVITRO,notforuseindiagnosticortherapeuticproceduresinvolvinghumansoranimals.Itmaycontainhazardousingredients. PleaserefertotheSafetyDataSheets(SDS)foradditionalinformationandproperhandlingprocedures.Disposeproductremaindersaccordingtolocalregulations.Thisdatasheetisasaccurateasreasonablyachievable,butNordic-Mubio​acceptsnoliabilityforanyinaccuraciesoromissionsinthisinformation.

References1.SignorettiS.,WaltregnyD.,DilksJ.,IsaakB.,LinD.,GarrawayL.,etal.(2000)p63isaprostatebasalcellmarkerandisrequiredforprostatedevelopment.AmJ.Pathol.157;1769-1775.2.WeinsteinM.H.,SignorettiS.,andLodaM.(2002)Diagnosticutilityofimmunohistochemicalstainingforp63,asensitivemarkerofprostaticbasalcells.Mod.Pathol.15(12);1302-13083.YangX.J.,LecksellK.,GaudinP.,andEpsteinJ.I.(1999)Rareexpressionofhigh-molekular-weightcytokeratininadenocarcinomaoftheprostategland:astudyof100casesofmetastaticandlocallyadvancedprostatecancer.Am.J.Surg.Pathol.23(2);147-152.4.BrowneTJ,HirschMS,BrodskyG,WelchWR,LodaMF,RubinMA.ProspectiveevaluationofAMACR(P504S)andbasalcellmarkersintheassessmentofroutineprostateneedlebiopsyspecimens.HumPathol.2004Dec;35(12):1462-8.5.JiangZ,LiC,FischerA,DresserK,WodaBA.UsinganAMACR(P504S)/34betaE12/p63cocktailforthedetectionofsmallfocalprostatecarcinomainneedlebiopsyspecimens.AmJClinPathol.2005Feb;123(2):231-6.

SafetyDatasheet(s)forthisproduct:NM_SodiumAzide/wp-content/uploads/SDS/AntibodySDSwithSodiumAzideNoridic-MUbio.pdf